CD24Fc as a non‐antiviral immunomodulator in COVID‐19 treatment  Drug: CD24Fc, drug: placebo  United States/severe coronavirus disease (COVID‐19)  230, all, 18 years and older  Treatment  Experimental: CD24Fc treatment
Single dose at Day 1, CD24Fc, 480 mg, diluted to 100 ml with normal saline, IV infusion in 60 min
Placebo comparator: placebo
Single dose at Day 1, normal saline solution 100 ml, IV infusion in 60 min  III  Primary (14 days):
Improvement of COVID‐19 disease status secondary (14 days):
Conversion rate of clinical status at Day 8 (7 days), conversion rate of clinical status at Day 15, hospital discharge time, all cause of death, duration of mechanical ventilation, duration of pressors, duration of ECMO, duration of oxygen therapy, length of hospital stay, absolute lymphocyte count  NCT04317040/Not yet recruiting,May‐May 2020–2022